Tayzen PharmLab
Development and production of pharmaceutical preparation industry
Service Platform (CDMO)
Shanghai Tayzen PharmLab Co., Ltd. was registered and established in November 2021 in the Lingang New Area of the China (Shanghai) Pilot Free Trade Zone, with a 6200 meter building ² A single building covering the development, pilot testing, and production sites of high-end pharmaceutical products.
Business scope
  • 26Term
    Previously led national and provincial
    level scientific research projects
  • 190More than articles
    Publish SCI papers
  • 120Term
    Domestic and foreign invention patent authorization
  • Core Management Team
    The core management team of Taizhen Biotechnology is composed of dozens of doctoral pharmacists, with rich experience in high-end formulation research and industrialization.
  • Core Technology Committee
    The Core Technology Committee is composed of several experts, including the Pharmaceutical Professional Committee of the Shanghai Pharmaceutical Association, the Discipline Evaluation Group of the State Council (Pharmacy), the Industrial Pharmacy Professional Committee of the Chinese Pharmaceutical Association, the National Thousand Talents Program, and the National Outstanding Youth Program.
  • Core Technology Team
    The core technology team has led 26 national and provincial scientific research projects in the field of new drug formulations, published over 190 SCI papers, and obtained 32 domestic and foreign invention patent authorizations (6 enterprise conversions), 2 national Class II new drug certificates, and 1 clinical approval in the field of nano drugs for treatment and diagnosis.
Factory facilities
Company dynamics